Free Trial Information
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...
Read More
BioCentury | Mar 11, 2021
Emerging Company Profile

AgomAb: antibodies driving tissue regeneration and recovery

...II/III study to treat Alzheimer’s disease and is planning a Phase II trial for Parkinson’s disease.Helixmith Co. Ltd....
Read More
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
Read More
BioCentury | Sep 24, 2019
Clinical News

Helixmith struggling to explain Phase III gene therapy results

...found in patients who were in the placebo group. Early Tuesday in Korea, shares of Helixmith Co. Ltd....
...shaved about W1.1 trillion ($981.3 million) from its market cap. Helixmith -- previously known as ViroMed...
...testing the same therapy to treat diabetic foot ulcers and amyotrophic lateral sclerosis. Paul Bonanos, Associate Editor VM202 Helixmith Co. Ltd. Helixmith Co. Ltd. ...
Read More
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
Read More
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed...
Read More
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed...
Read More
BioCentury | Feb 23, 2018
Company News

USAID unveils project to prevent viral pandemics

In a policy paper published in Science , the U.S. Agency for International Development (USAID) and others announced plans to start the Global Virome Project (GVP) which aims to take a pro-active approach to identifying viruses...
Read More
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

...to treat leukodystrophy, spinal muscular atrophy (SMA) and neuropathy from GlaxoSmithKline plc., RegenxBio Inc. and ViroMed...
...Inc. (NASDAQ:RGNX), Rockville, Md. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. University of Florida, Gainesville, Fla. ViroMed...
Read More
BioCentury | Sep 22, 2017
Clinical News

Oncolytics treats first patient in Phase Ib of Reolysin for MM

...survival (OS) Status: Phase Ib started Milestone: Preliminary Phase Ib data (1Q18) Jennie Walters Imnovid lenalidomide pelareorep pomalidomide Reolysin Revlimid VM202 Myeloma UK Oncolytics Biotech Inc. Helixmith Co. Ltd. Celgene...
Read More
Items per page:
1 - 10 of 24
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...
Read More
BioCentury | Mar 11, 2021
Emerging Company Profile

AgomAb: antibodies driving tissue regeneration and recovery

...II/III study to treat Alzheimer’s disease and is planning a Phase II trial for Parkinson’s disease.Helixmith Co. Ltd....
Read More
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
Read More
BioCentury | Sep 24, 2019
Clinical News

Helixmith struggling to explain Phase III gene therapy results

...found in patients who were in the placebo group. Early Tuesday in Korea, shares of Helixmith Co. Ltd....
...shaved about W1.1 trillion ($981.3 million) from its market cap. Helixmith -- previously known as ViroMed...
...testing the same therapy to treat diabetic foot ulcers and amyotrophic lateral sclerosis. Paul Bonanos, Associate Editor VM202 Helixmith Co. Ltd. Helixmith Co. Ltd. ...
Read More
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
Read More
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed...
Read More
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed...
Read More
BioCentury | Feb 23, 2018
Company News

USAID unveils project to prevent viral pandemics

In a policy paper published in Science , the U.S. Agency for International Development (USAID) and others announced plans to start the Global Virome Project (GVP) which aims to take a pro-active approach to identifying viruses...
Read More
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

...to treat leukodystrophy, spinal muscular atrophy (SMA) and neuropathy from GlaxoSmithKline plc., RegenxBio Inc. and ViroMed...
...Inc. (NASDAQ:RGNX), Rockville, Md. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. University of Florida, Gainesville, Fla. ViroMed...
Read More
BioCentury | Sep 22, 2017
Clinical News

Oncolytics treats first patient in Phase Ib of Reolysin for MM

...survival (OS) Status: Phase Ib started Milestone: Preliminary Phase Ib data (1Q18) Jennie Walters Imnovid lenalidomide pelareorep pomalidomide Reolysin Revlimid VM202 Myeloma UK Oncolytics Biotech Inc. Helixmith Co. Ltd. Celgene...
Read More
Items per page:
1 - 10 of 24